← Leaderboards
John Robinson Singleton
University Of Utah
$10,547,748
Attributed
$21,843,737
Total exposure
13
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,843,737 · 13
By mechanism
U01$7,339,663 · 1
R01$7,251,668 · 2
U24$2,781,607 · 1
R61$2,298,698 · 1
DP3$1,442,115 · 1
U10$298,000 · 1
Top collaborators
- A Gordon Smith16 shared
- Christopher S. Coffey4 shared
- Merit E Cudkowicz4 shared
- Josh Leitch Bonkowsky3 shared
- Mikhail I. Nemenov3 shared
- Aaron I. Vinik3 shared
Most similar at University Of Utah
Same institution · by research overlap
- A Gordon Smith$10,319,540
- William L. Carroll$23,653,738
- Mary C. Beckerle$16,693,203
- Saundra S Buys$6,655,241
- Robert M Silver$8,954,120
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsUtahPainEffective TherapyNerve FibersDiabetes MellitusNeuropathyDensityFiberRandomizedAffectNerveDiabeticAxonSensory NeuropathyObesitySymptomsDistalSkinBasePeripheral NervesSensoryCutaneousMetabolic Syndrome
Grant awards (39)
Discovery and Validation of a Novel Response Biomarker Signature for Painful Peripheral Neuropathy$795,734
R61 · FY2025 · NS
The Utah Regional Network for Excellence in Neuroscience Clinical Trials (UR-NEXT)$423,100
U24 · FY2025 · NS · contact PI
The Utah Regional Network for Excellence in Neuroscience Clinical Trials (UR-NEXT)$410,407
U24 · FY2024 · NS · contact PI
Discovery and Validation of a Novel Response Biomarker Signature for Painful Peripheral Neuropathy$502,796
R61 · FY2023 · NS
The Utah Regional Network for Excellence in Neuroscience Clinical Trials (UR-NEXT)$423,100
U24 · FY2023 · NS · contact PI
Discovery and Validation of a Novel Response Biomarker Signature for Painful Peripheral Neuropathy$1,000,168
R61 · FY2022 · NS
The Utah Regional Network for Excellence in Neuroscience Clinical Trials$305,000
U24 · FY2022 · NS · contact PI
The Utah Regional Network for Excellence in Neuroscience Clinical Trials$305,000
U24 · FY2021 · NS · contact PI
Topiramate as a Disease Altering Therapy for CSPN$874,009
U01 · FY2020 · NS
The Utah Regional Network for Excellence in Neuroscience Clinical Trials$305,000
U24 · FY2020 · NS · contact PI
Topiramate as a Disease Altering Therapy for CSPN$1,847,422
U01 · FY2019 · NS
Acitivity for Diabetic Polyneuropathy: The ADAPT Study$642,156
R01 · FY2019 · DK · contact PI
The Utah Regional Network for Excellence in Neuroscience Clinical Trials$305,000
U24 · FY2019 · NS · contact PI
Topiramate as a Disease Altering Therapy for CSPN$2,219,043
U01 · FY2018 · NS
Acitivity for Diabetic Polyneuropathy: The ADAPT Study$657,214
R01 · FY2018 · DK · contact PI
The Utah Regional Network for Excellence in Neuroscience Clinical Trials$305,000
U24 · FY2018 · NS · contact PI
Topiramate as a Disease Altering Therapy for CSPN$2,399,189
U01 · FY2017 · NS
Acitivity for Diabetic Polyneuropathy: The ADAPT Study$666,505
R01 · FY2017 · DK · contact PI
The Utah Regional Network for Excellence in Neuroscience Clinical Trials$298,000
U10 · FY2017 · NS · contact PI
Acitivity for Diabetic Polyneuropathy: The ADAPT Study$677,268
R01 · FY2016 · DK · contact PI
Acitivity for Diabetic Polyneuropathy: The ADAPT Study$662,769
R01 · FY2015 · DK · contact PI
Acitivity for Diabetic Polyneuropathy: The ADAPT Study$24,288
R01 · FY2015 · DK · contact PI
Developing Corneal Confocal Microscopy as a Screening Tool and Biomarker for Diabetic Neuropathy$1,442,115
DP3 · FY2014 · DK
The Utah Diabetic Neuropathy Study$604,095
R01 · FY2011 · DK
The Utah Diabetic Neuropathy Study$626,509
R01 · FY2010 · DK
The Utah Diabetic Neuropathy Study$119,760
R01 · FY2010 · DK
The Utah Diabetic Neuropathy Study$636,864
R01 · FY2009 · DK
The Utah Diabetic Neuropathy Study$621,070
R01 · FY2008 · DK
NEUROPATHY ASSOCIATED WITH IMPAIRED GLUCOSE TOLERANCE$3,438
M01 · FY2008 · RR · contact PI
NEUROPATHY ASSOCIATED WITH IMPAIRED GLUCOSE TOLERANCE$21,902
M01 · FY2007 · RR · contact PI
NEUROPATHY ASSOCIATED WITH IMPAIRED GLUCOSE TOLERANCE$52,740
M01 · FY2006 · RR · contact PI
NEUROPATHY ASSOCIATED WITH IMPAIRED GLUCOSE TOLERANCE$54,113
M01 · FY2005 · RR
Impaired Glucose Tolerance Causes Neuropathy$403,505
R01 · FY2004 · NS
Neuropathy associated with impaired glucose tolerance$34,947
M01 · FY2004 · RR
MYOPATHY ASSOCIATED WITH ELEVATED CPK IN THE PICU$786
M01 · FY2004 · RR
Impaired Glucose Tolerance Causes Neuropathy$391,560
R01 · FY2003 · NS
Impaired Glucose Tolerance Causes Neuropathy$518,105
R01 · FY2002 · NS
IGF-I RECEPTOR PREVENTS APOPTOSIS IN HUMAN NEUROBLASTS$134,730
K08 · FY2001 · NS
IGF-I RECEPTOR PREVENTS APOPTOSIS IN HUMAN NEUROBLASTS$129,330
K08 · FY2000 · NS